GALWAY, Ireland - Medtronic plc (NYSE:MDT) announced today it has completed its acquisition of Scientia Vascular, a privately-held medical device company based in Salt Lake City, for $550 million, subject to customary adjustments, according to a press release statement. The acquisition represents roughly 0.5% of Medtronic’s $103 billion market capitalization.
The transaction includes potential undisclosed earn-out and milestone payments following the acquisition. Scientia Vascular, which employs approximately 310 people, develops guidewires and catheters for neurovascular procedures.
The acquisition adds access technologies to Medtronic’s neurovascular product portfolio. Scientia’s products are designed to help physicians navigate complex cerebral vasculature when treating conditions such as strokes and aneurysms.
"Since its founding, Scientia has been driven by a commitment to improving patients’ lives and supporting the physicians who care for them," said Rick Randall, CEO of Scientia. "Joining Medtronic is an exciting next step for our team, as their Mission closely aligns with the values that have guided Scientia from the beginning."
Linnea Burman, senior vice president and president of Medtronic’s Neurovascular business, stated that the addition of Scientia’s access technologies strengthens the company’s ability to support physicians with neurovascular solutions.
The company said the acquisition is expected to be minimally dilutive to Medtronic adjusted earnings per share in fiscal year 2027 and accretive thereafter. According to InvestingPro analysis, Medtronic currently trades below its Fair Value, suggesting the stock may be undervalued. The company has maintained dividend payments for 50 consecutive years and offers a 3.6% dividend yield. For deeper insights, investors can access Medtronic’s comprehensive Pro Research Report, one of 1,400+ available on InvestingPro.
Medtronic, headquartered in Galway, Ireland, employs more than 95,000 people across over 150 countries. The company manufactures medical technologies including cardiac devices, surgical robotics, insulin pumps and patient monitoring systems.
In other recent news, Medtronic reported its fourth-quarter fiscal 2026 results, showcasing revenues that surpassed both TD Cowen and market expectations. The company’s earnings per share met forecasts at $1.55, despite a 4.3% decline year-over-year, partially attributed to a Blackstone charge and the MiniMed separation. Medtronic’s cardiovascular and spine segment demonstrated significant growth, with a 78% worldwide increase and notable market share gains in the United States. The company achieved a 6.6% organic revenue growth for the quarter, exceeding the 5.9% consensus estimate. Fiscal 2027 guidance projects a 5.8% organic growth rate, consistent with the previous fiscal year. UBS, Truist Securities, and Bernstein SocGen Group have all adjusted their price targets for Medtronic, citing various factors such as execution outlook and margin softness. UBS lowered its target to $85, Truist to $86, and Bernstein SocGen to $97, with each firm maintaining their respective ratings. Meanwhile, BTIG highlighted Stryker’s Mako robotic system as a leader in the shift towards robotics in ambulatory surgery centers, maintaining a Buy rating and a $379 price target for the company.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
The fastest way to find out is with our Fair Value calculator. We use a mix of 17 proven industry valuation models for maximum accuracy. Get the bottom line for MDT plus thousands of other stocks and find your next hidden gem with massive upside.